

Please check your submission one more time.

Then scroll all the way down to the bottom of this page to submit your abstract.

After you review your submission, scroll all the way down to the bottom of this page to submit your abstract. Please note that if any areas are incomplete, you will be prompted to go back and complete before submitting your abstract. To make updates, select any step from the tool bar menu and edit accordingly. Be sure to save your changed before moving on. If you make edits to this submission, you must complete this Session Confirmation step each time so it can be saved in the system. **Failure to complete this step may result in your submission being marked incomplete and withdrawn after the submission deadline.**

Sc Infliximab . the Innovative Linking Sustainability Based on Switch, the Cost Avoidance and Loss & Gain Productivity .

Tanaka E¹, Muzy G², Azevedo VF³, Furtado D¹, Schiavetti B¹

¹TNK, CURITIBA, PR, Brazil, ²Muzy Clinic, SAO PAULO, SP, Brazil, ³Federal University of Paraná, Curitiba, Brazil

Problem Statement: Infliximab, a treatment for rheumatoid arthritis (RA), inflammatory bowel diseases (IBD), and psoriatic arthritis (PA), is commonly administered via IV but now has a new SC option. Patients should consider personal needs and consult with healthcare providers when deciding to switch. This study addresses whether infliximab can transition from IV to SC and the financial and productivity implications of the new formulation.

Description: The SC infliximab offers a self-administered alternative for patients with difficulties receiving IV treatment. Clinical trials confirm SC's comparability to IV in efficacy and safety, allowing patients to maintain disease control. The switch entails a revised dosing schedule and patient training. Cost benefits and productivity impacts of the SC option differ by region due to cultural, lifestyle, and economic variables.

Lessons Learned: Clinical trials show SC infliximab is not less effective or safe compared to IV, ensuring consistent disease management post-switch. Data from regions with variable RA & IBD and psoriasis & PA incidence suggest significant cost avoidance with SC adoption, potentially treating up to 1.67 million additional patients annually based on a 19.18% reduction in patient costs. These savings correlate with productivity gains.

Stakeholder Perspective: This includes a diverse group such as patients/caregivers, healthcare providers, insurers, academia, and the pharmaceutical industry.

Case Study ID#:

140695

Submitter's E-mail Address:

eliotanaka@gmail.com

Program Selection:

Case Studies

Main Topic/Taxonomy:

Patient-Centered Research

Subtopics:

Patient-Centered Research: Instrument Development, Validation, & Translation

Patient-Centered Research: Patient Engagement

Patient-Centered Research: Patient-reported Outcomes & Quality of Life Outcomes

Patient-Centered Research: Stated Preference & Patient Satisfaction

Primary Specific Diseases & Cond./Specialized Treatment Areas:

STA: Biologics & Biosimilars

Additional Diseases & Conditions/Specialized Treatment Areas:

SDC: Sensory System Disorders (Ear, Eye, Dental, Skin) STA: Biologics & Biosimilars

First author***Presenting Author***

Elio Tanaka, MD
HEALTH ECONOMIC RESEARCH
TNK
Rua Deputado Leoberto Leal
casa
CURITIBA, PR, 81510090
Brazil

Phone Number: 41996241082

Student? No

Email Address: eliotanaka@gmail.com

* Membership Number 23753

Second author

Guilherme Muzy, MD , PhD
RESEARCH
Muzy Clinic
RUA DEP LEOBERTO LEAL ,
SAO PAULO, SP, 81510-090
Brazil

Phone Number: 41996241082

Email Address: guilherme@clinicamuzy.com.br

Third author

Valderilio Feijó Azevedo, MD, MBA PhD
Federal University of Paraná
Rua General Carneiro 181
Curitiba, CEP 80440-080
Brazil

Phone Number: +55 41 30496504

Email Address: valderilio@edumed.med.br

Fourth author

Davi Furtado, MD
HEALTH ECONOMIC RESEARCH
TNK
Rua Deputado Leoberto Leal
casa
CURITIBA, PR, 81510090
Brazil

Phone Number: 41996241082

Email Address: davicfurtado@yahoo.com.br

Fifth author

Bianca Schiavetti, MD
HEALTH ECONOMIC RESEARCH
TNK
Rua Deputado Leoberto Leal
casa
CURITIBA, PR, 81510090
Brazil

Phone Number: 41996241082

Email Address: biancalps@hotmail.com

Submitter

Elio Tanaka, MD
HEALTH ECONOMIC RESEARCH
TNK
Rua Deputado Leoberto Leal
casa
CURITIBA, PR, 81510090
Brazil

Phone Number: 41996241082

Student? No

Email Address: eliotanaka@gmail.com

* Membership Number 23753

FINAL STEPS

Enter your name (or the name of the lead author) in the certification statement below. - *(Required)*

I, , affirm that this case study conforms to all the case study policies and procedures as stated in the Call for Abstracts. I certify that the authors named are familiar with the presented material, agree with the results as stated (original research), and have specifically consented to be included as authors. I certify, represent, and warrant that I have the right to publish this abstract as submitted and agree to indemnify ISPOR from any claims arising from this material, and assign copyright of this abstract to ISPOR. **(This abstract will not be accepted if this step is not complete.)**

Click [HERE](#) to print this page now.

CONCLUDE SUBMISSION